I discussed this on several occasions with microbiologists in Oxford. My recollection of their conclusions was that the improvements in process outcomes reported from the USA weren’t available in the UK because the way that antibiotics were already managed in the UK was much better. So expectations shouldn’t be based on transferability of fractional improvement…

There’s a worked example of an economic evaluation in an Appendix of this HTA: http://www.nice.org.uk/nicemedia/pdf/CG47Guidance.pdf

Jonathan

On 17 Jan 2014, at 10:48, Myers Martin (LTHTR) <[log in to unmask]> wrote:

I would be grateful if anyone could share their experiences on whether that the introduction of procalcitonin reduced antibiotic use, reduced bed days and reduced admission.

Thanks

martin

------ACB discussion List Information-------- This is an open discussion list for the academic and clinical community working in clinical biochemistry. Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content. ACB Web Site http://www.acb.org.uk Green Laboratories Work http://www.laboratorymedicine.nhs.uk List Archives http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html List Instructions (How to leave etc.) http://www.jiscmail.ac.uk/